PHVS — Pharvaris N.V. stock price, charts and financials

Latest market price

33.87

+1.62+5.02%

Overview Short InterestFilings

PHVSQT77Pharvaris N.V.·NASDAQ

Overview Short InterestFilings

33.87+5.02%

News

Up 5.0% — Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment (SeekingAlpha).

Medium confidence

Loading chart...

Signal & projected range

QT Score upgradeHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

VCEL+0.63%$46.34 ANAB+2.74%$55.13 KLRA+4.56%$18.11 IMNM+8.91%$25.06 MLYS+2.79%$26.50 PGEN-1.21%$6.53 AMLX+8.43%$21.87 BCRX+2.38%$9.02

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	1.72%	Shs Outstand	69.88M	Perf Week	0.65%

Market Cap	2.37B	Forward P/E	-	EPS next Y	-2.83	Insider Trans	-32.61%	Shs Float	33.05M	Perf Month	1.96%

Enterprise Value	2.08B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	1.63%	Perf Quarter	12.82%

Income	-198.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	2.69	Perf Half Y	23.48%

Sales	0.00	P/B	8.67	EPS next Y	7.84%	ROA	-65.13%	Short Interest	1.14M	Perf YTD	22.05%

Book/sh	3.91	P/C	8.30	EPS next 5Y	-	ROE	-67.40%	52W High	36.60 -7.46%	Perf Year	69.35%

Cash/sh	4.08	P/FCF	-	EPS past 3/5Y	-	ROIC	-72.82%	52W Low	19.56 73.16%	Perf 3Y	100.30%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	4.77% 4.46%	Perf 5Y	136.03%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-20.38%	Oper. Margin	0.00%	ATR (14)	1.54	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	11.24	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	51.62	Recom	2.08

Dividend Gr. 3/5Y	-	Current Ratio	11.24	EPS Q/Q	17.65%	SMA20	-0.80%	Beta	-2.45	Target Price	52.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	3.18%	Rel Volume	0.60	Prev Close	32.25

Employees	129	LT Debt/Eq	0.00	Earnings	Aug 11	SMA200	20.62%	Avg Volume	418.18K	Price	33.87

IPO Date	Feb 04, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.26% -	Net Debt/EBITDA	1.48	Volume	250,542	Change	5.02%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-15-26	Initiated	Wells Fargo	Overweight	$55
Jun-25-26	Reiterated	Morgan Stanley	Overweight	$41 → $46
May-13-26	Reiterated	UBS		$75 → $74
Apr-08-26	Initiated	Wolfe Research	Outperform	$42
Mar-09-26	Initiated	RBC Capital	Outperform	$52
Dec-04-25	Reiterated	Morgan Stanley	Overweight	$41
Dec-04-25	Reiterated	Guggenheim	Buy	$39
Dec-04-25	Reiterated	Oppenheimer	Outperform	$42 → $50
Dec-03-25	Reiterated	Leerink Partners		$28 → $38
Oct-15-25	Initiated	H.C	Buy	$60

Latest News

Aug-04-26

Aug-04-2611:04AM

Pharvaris: One Molecule Could Reshape Both Sides Of HAE TreatmentSeekingAlpha

Jul-31-26

Jul-31-2610:56AM

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Betzacks.com

Jul-24-26

Jul-24-2607:01AM

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?fool.com

Jul-22-26

Jul-22-2606:53AM

Pharvaris Announces Publication Of Comprehensive Review On Bradykinin Biology And B2R Antagonism In Clinical Reviews In Allergy & ImmunologyBenzinga

06:50AM

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedemaglobenewswire.com

Jul-15-26

Jul-15-2601:01PM

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buyzacks.com

07:03AM

Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55Benzinga

Jul-14-26

Jul-14-2610:56AM

Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Tradezacks.com

Jul-06-26

Jul-06-2606:53AM

Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Attacks; PDUFA Target Action Date Set April 23, 2027Benzinga

06:50AM

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacksglobenewswire.com

Jun-25-26

Jun-25-2601:33PM

Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46Benzinga

Jun-15-26

Jun-15-2606:52AM

Pharvaris Highlights New Deucrictibant Data at EAACI 2026, Says HAE Treatment Data Support On-Demand and Preventive UseBenzinga

Jun-12-26

Jun-12-2607:13PM

Pharvaris N.V. (PHVS) Presents at World Orphan Drug Congress (WODC) USA 2026 - SlideshowSeekingAlpha

Company

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0	0
Selling, General and Administrative Excl. Other	51	51	34	31	22	7	3	1
Research and Development	140	107	71	60	42	25	7	4
Other Operating Expense	1	0	0	0	0	1	0	0
Operating Income	-192	-158	-105	-91	-64	-33	-10	-5
Interest Expense	0	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-4	14	-3	12	14	-1	0	0
Net Income Before Taxes	-196	-143	-108	-80	-50	-34	-10	-5
Income Taxes	2	2	1	1	0	0	0	0
Consolidated Net Income	-198	-145	-109	-80	-51	-34	-10	-5
Net Income From Continuing Operations	-198	-145	-109	-80	-51	-34	-10	-5
Net Income	-198	-145	-109	-80	-51	-34	-10	-5
EPS (Recurring)	-3.35	-2.68	-2.84	-2.39	-1.67	-0.97	-0.28	-0.17
EPS (Basic, Before Extraordinaries)	-3.35	-2.68	-2.84	-2.39	-1.67	-0.97	-0.28	-0.17
EPS (Diluted)	-3.35	-2.68	-2.84	-2.39	-1.67	-0.97	-0.28	-0.17
EBITDA	-195	-158	-108	-91	-50	-34	-10	-5
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—
Shares Outstanding	59	54	38	34	30	31	32	32
Market Capitalization	1,637	1,035	1,066	383	432	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Modig Berndt	Chief Executive Officer	Jul 13 '26	Sale	34.97	2,292	80,154	132,917	Jul 15
Lesage Anne	Chief Early Development	Jun 30 '26	Option Exercise	7.47	27,872	208,142	86,622	Jul 01
Schikan Johannes Gerardus Christiaan Petrus	Director	Jun 30 '26	Sale	35.49	30,712	1,090,049	315,167	Jul 01
Lesage Anne	Chief Early Development	Jun 30 '26	Sale	35.48	58,575	2,078,527	58,750	Jul 01
Lesage Anne	Chief Early Development	Jun 29 '26	Option Exercise	5.22	10,600	55,300	67,050	Jul 01
Schikan Johannes Gerardus Christiaan Petrus	Director	Jun 29 '26	Sale	35.07	9,288	325,697	345,879	Jul 01
Lesage Anne	Chief Early Development	Jun 29 '26	Sale	35.06	17,597	616,926	56,450	Jul 01
Lu Peng	Chief Medical Officer	Jun 26 '26	Sale	34.00	14,700	499,847	65,631	Jun 29
Lu Peng	Chief Medical Officer	Jun 26 '26	Option Exercise	2.59	14,700	38,073	80,331	Jun 29
Lesage Anne	Chief Early Development	Jun 25 '26	Sale	35.12	4,600	161,561	56,450	Jun 29
Lesage Anne	Chief Early Development	Jun 25 '26	Option Exercise	4.73	2,300	10,871	58,750	Jun 29
Lu Peng	Chief Medical Officer	Jun 25 '26	Option Exercise	2.59	15,000	38,850	80,631	Jun 29
Lu Peng	Chief Medical Officer	Jun 25 '26	Sale	34.60	15,000	518,985	65,631	Jun 29
Lu Peng	Chief Medical Officer	Jun 18 '26	Option Exercise	2.59	300	777	65,931	Jun 23
Lu Peng	Chief Medical Officer	Jun 18 '26	Sale	34.00	300	10,200	65,631	Jun 23

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.